Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...

The phase 3 trial of valoctocogene roxaparvovec for severe hemophilia A showed it reduced bleeding events as well as the use of factor VIII concentrates. A phase 3 trial of valoctocogene roxaparvovec, ...

Valoctocogene roxaparvovec delivers a B-domain–deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a ...

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec conferred sustained bleeding control at 2 years among a cohort of men with severe ...

Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...

Clinical data have been published for a gene therapy for hemophilia A that is approaching the market — valoctocogene roxaparvovec (Roctavian), which is currently under review by the US Food and Drug ...

The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions. By Todd Campbell – May 28, 2019 at 7:46PM EST Hemophilia A ...

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...

Assay for factor VIII activity was done by a one-stage activated partial-thromboplastin-time method as previously described. 3 The standard for activity was either frozen normal plasma from a person ...